While the majority of the world’s population is fighting and battling the COVID-19 pandemic, several pharmacological treatments have been discovered, each with different benefits. Meanwhile, vaccination against COVID-19 continues, and a third vaccination is in progress in some areas. Initial data from Israel suggest that the fourth dose of Pfizer/BioNTech or Moderna coronavirus vaccines could lead to an increase in already formed antibodies. This will be more than has already been produced after the third dose but may not be sufficient to protect against breakthrough infection with a new strain called the Omicron strain. Israel has started rolling out a fourth COVID-19 vaccine for the population aged 60 and over as Omicron cases are on the rise. 
Dr Sheba, Medical Center’s Director of Infection Prevention and Control. According to Gili Regev Yochai, “This is a very preliminary result. This is pre-publication, but I’m releasing it because the public understands that all the information, they can do about the 4th dose is urgent.” And what we do see is that the Pfizer vaccine can see an increase or an increase in antibodies and neutralize antibodies after two weeks. That’s a pretty good increase. It’s slightly higher than after the third dose,” said Regev Yochai. “But this probably won’t be enough for Omicron.” Do I need a 4th dose of the Covid19 vaccine? U.S. health officials have said no. In December, Sheba Medical Center began tracking the fourth vaccination in healthy people before distributing additional boosters to at-risk groups, and this is the first study of its kind. The study included 154 healthcare workers who received a fourth dose of Pfizer/BioNTech vaccine, 120 people who received the fourth dose of Moderna vaccine, and a control group of workers who did not receive the fourth dose. Regev Yochai said the researchers found an increase in antibodies among those who received the fourth dose.
In conclusion, the administration of the fourth dose of Covid-19 vaccine has shown to increase the level of the antibodies in the body, governments are encouraged to help provide the vaccine and make it readily available for the people. For more effective treatments, elderly patients above 60 should be given preferential treatment as they are at higher risk of developing the disease faster and are often associated with poor disease outcomes. Among those receiving the fourth dose, the antibody levels needed to prevent omicron infection would be “too high for a vaccine, no matter how good the vaccine is,” he said. However, she said the vaccinated people had slightly fewer infections compared to the control group. Regev Yochay added, “There were no significant differences between those receiving the Pfizer/BioNTech dose compared to Moderna.” Given the observations above, it would be desirable to implement a decision to allow a quaternary vaccine for the vulnerable, and I think it is probably the right decision as it will help reduce the spread. symptoms,” he said. said. “This may provide a small benefit, but it may not be sufficient to support the decision to provide it to the entire population.